Capsaicin: May increase the risk of cough w/ ACE inhibitors, risk of bleeding w/ concurrent use of antiplatelet agents; avoid concomitant use of barbiturates as acute use of capsaicin is associated w/ inhibitor of cytochrome P450 enzymes & chronic use w/ increased levels of the enzymes. Increased absorption to theophylline may occur. Monitor theophylline levels & signs & symptoms of theophylline toxicity. Diclofenac Na: Decrease antihypertensive & natriuretic effect of ACE inhibitors; increased BP & interference w/ BP control w/ β-blockers. Co-administration of β-glucan resulted in lethal GI damage in mice. May increase risk of GI hemorrhage w/ Ca channel blockers. Increased spinal hematomas in combination w/ danaparoid; may predispose patient to gastropathy, increased risk of bleeding & nephropathy w/ feverfew; additive GI distress may occur w/ gossypol; caution w/ concomitant use of ibandronate due to risk of GI irritation; risk for CNS stimulation & convulsive seizures w/ levofloxacin & ofloxacin. Increased methotrexate levels & toxicity. Reduction of partial clearance of quinidine by N-oxidation by 33%. Increased risk of bleeding w/ SSRIs. Hypoglycemia may occur w/ sulfonylureas. May be associated w/ anemia or oliguria in liver transplant patients receiving tacrolimus. Exercise caution w/ oral anticoagulants.